Cariprazine: First Global Approval.
Article Details
- CitationCopy to clipboard
McCormack PL
Cariprazine: First Global Approval.
Drugs. 2015 Nov;75(17):2035-43. doi: 10.1007/s40265-015-0494-7.
- PubMed ID
- 26510944 [ View in PubMed]
- Abstract
Cariprazine (Vraylar) is an oral atypical antipsychotic originated by Gedeon Richter. It is a potent dopamine D3 and D2 receptor partial agonist, which preferentially binds to the D3 receptor. Cariprazine also has partial agonist activity at serotonin 5-HT1A receptors. In September 2015, cariprazine received its first global approval in the USA for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder. It is also in development in a variety of countries for the treatment of schizophrenia with predominant negative symptoms (phase III), as adjunctive therapy for major depressive disorder (phase II/III) and for the treatment of bipolar depression (phase II). This article summarizes the milestones in the development of cariprazine leading to this first approval for schizophrenia and manic or mixed episodes associated with bipolar I disorder.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Cariprazine 5-hydroxytryptamine receptor 1A Protein Humans UnknownPartial agonistDetails Cariprazine 5-hydroxytryptamine receptor 2A Protein Humans UnknownAntagonistDetails Cariprazine 5-hydroxytryptamine receptor 2B Protein Humans UnknownAntagonistDetails Cariprazine Dopamine D2 receptor Protein Humans UnknownPartial agonistDetails Cariprazine Dopamine D3 receptor Protein Humans UnknownPartial agonistDetails Cariprazine Histamine H1 receptor Protein Humans UnknownAntagonistDetails